PL379544A1 - 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych - Google Patents

1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych

Info

Publication number: PL379544A1
Authority: PL; Poland
Prior art keywords: disease; hiv; treatment; syndrome; diabetes
Prior art date: 2002-09-09

Application number

PL379544A

Other languages

English (en)

Inventor

Celia Dominguez

Dawei Zhang

Kelvin K.C. Sham

Guo-Qiang Cao

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-09

Filing date

2003-09-08

Publication date

2006-10-02

2003-09-08 Application filed by Amgen Inc. filed Critical Amgen Inc.

2006-10-02 Publication of PL379544A1 publication Critical patent/PL379544A1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)

PL379544A 2002-09-09 2003-09-08 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych PL379544A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40917602P	2002-09-09	2002-09-09

Publications (1)

Publication Number	Publication Date
PL379544A1 true PL379544A1 (pl)	2006-10-02

Family

ID=31978728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL379544A PL379544A1 (pl)	2002-09-09	2003-09-08	1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych

Country Status (11)

Country	Link
US (1)	US6967254B2 (pl)
EP (1)	EP1542680B1 (pl)
JP (1)	JP2006501263A (pl)
AT (1)	ATE355839T1 (pl)
AU (1)	AU2003273295B2 (pl)
CA (1)	CA2497007A1 (pl)
DE (1)	DE60312342T2 (pl)
ES (1)	ES2283811T3 (pl)
MX (1)	MXPA05002513A (pl)
PL (1)	PL379544A1 (pl)
WO (1)	WO2004022055A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1812071A2 (en) *	2004-10-13	2007-08-01	PTC Therapeutics, Inc.	Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
CA2618068C (en) *	2005-08-05	2016-02-16	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007035906A2 (en) *	2005-09-21	2007-03-29	The Regents Of The University Of California	Systems and methods for imaging-treatment of pain
US9187455B2 (en) *	2009-02-23	2015-11-17	Hoffmann-La Roche Inc.	Substituted pyridazines as PDE10A inhibitors
DE102011055815A1 (de) *	2011-11-29	2013-05-29	Aicuris Gmbh & Co. Kg	Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
WO2013082458A1 (en)	2011-12-02	2013-06-06	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
CN111067911A (zh) *	2018-10-18	2020-04-28	刘琦	白头翁皂苷b4抗急性痛风性关节炎的医药用途
CN115957218B (zh) *	2021-10-08	2024-11-05	中国医学科学院药物研究所	一种ccr5抑制剂及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4935278B1 (pl) *	1970-09-26	1974-09-20
CA994338A (en)	1973-09-25	1976-08-03	Merck Sharp And Dohme (I.A.) Corp. U.S.A. (Doing Business As Laboratoire S Merck Frosst Laboratories)	Compositions containing heterocyclic bronchodilating agents
JPS5821251B2 (ja) *	1978-08-28	1983-04-28	旭化成株式会社	乾式画像形成材料
IL86926A (en) *	1987-07-13	1992-07-15	Sterling Drug Inc	Diphenyl-1h-pyrazole-1-alkanamides,their preparation and antiarrhythmic compositions containing them
US4898880A (en) *	1989-03-22	1990-02-06	Sterling Drug Inc.	N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
US5191084A (en) *	1991-05-01	1993-03-02	American Home Products Corporation	Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
US5559137A (en) *	1994-05-16	1996-09-24	Smithkline Beecham Corp.	Compounds
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
US6514977B1 (en) *	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
PL336990A1 (en) *	1997-05-22	2000-07-31	Searle & Co	3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
JP2002502380A (ja) *	1997-05-22	2002-01-22	ジー．ディー．サールアンドカンパニー	ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US20020156104A1 (en) *	1997-06-13	2002-10-24	Jerry L. Adams	Novel pyrazole and pyrazoline substituted compounds
CA2327185A1 (en) *	1998-04-08	1999-10-14	Abbott Laboratories	Pyrazole inhibitors of cytokine production
US6548529B1 (en) *	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
DK1206474T3 (da) *	1999-08-27	2004-10-04	Abbott Lab	Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
US6821971B2 (en) *	2001-09-20	2004-11-23	The Procter & Gamble Company	Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
US6677337B2 (en) *	2002-03-19	2004-01-13	The Procter & Gamble Company	1,2-dihydropyrazol-3-ones which controls inflammatory cytokines

2003
- 2003-09-08 AT AT03755794T patent/ATE355839T1/de not_active IP Right Cessation
- 2003-09-08 US US10/658,298 patent/US6967254B2/en not_active Expired - Fee Related
- 2003-09-08 ES ES03755794T patent/ES2283811T3/es not_active Expired - Lifetime
- 2003-09-08 AU AU2003273295A patent/AU2003273295B2/en not_active Ceased
- 2003-09-08 WO PCT/US2003/028067 patent/WO2004022055A1/en not_active Ceased
- 2003-09-08 EP EP03755794A patent/EP1542680B1/en not_active Expired - Lifetime
- 2003-09-08 DE DE60312342T patent/DE60312342T2/de not_active Expired - Fee Related
- 2003-09-08 PL PL379544A patent/PL379544A1/pl not_active Application Discontinuation
- 2003-09-08 CA CA002497007A patent/CA2497007A1/en not_active Abandoned
- 2003-09-08 JP JP2004534741A patent/JP2006501263A/ja active Pending
- 2003-09-08 MX MXPA05002513A patent/MXPA05002513A/es active IP Right Grant

Also Published As

Publication number	Publication date
DE60312342D1 (de)	2007-04-19
WO2004022055A1 (en)	2004-03-18
WO2004022055B1 (en)	2005-01-13
ATE355839T1 (de)	2007-03-15
ES2283811T3 (es)	2007-11-01
AU2003273295B2 (en)	2007-03-22
DE60312342T2 (de)	2007-07-12
EP1542680B1 (en)	2007-03-07
EP1542680A1 (en)	2005-06-22
MXPA05002513A (es)	2005-05-27
US6967254B2 (en)	2005-11-22
AU2003273295A1 (en)	2004-03-29
CA2497007A1 (en)	2004-03-18
JP2006501263A (ja)	2006-01-12
US20040058918A1 (en)	2004-03-25

Legal Events

Date	Code	Title	Description
2012-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
WO2003099808A8 (en)	2009-02-05	Substituted heterocyclic compounds and methods of use
PL379544A1 (pl)	2006-10-02	1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych
US8124632B2 (en)	2012-02-28	Alkylsulfonyl-substituted thiazolide compounds
PL374732A1 (pl)	2005-10-31	Kompozycje farmaceutyczne jako inhibitory peptydazy dipeptydylowej IV (DPP-IV)
US20120108592A1 (en)	2012-05-03	Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses
IL176298A0 (en)	2006-10-05	IMIDAZO [4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
WO2006058064A3 (en)	2006-10-05	Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2004046159A8 (en)	2005-06-30	Antiviral nucleoside derivatives
NO2008013I1 (no)	2008-09-08	Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt, saerling monofosfatet, pluss metformin, eventuelt i form av et farmasoytisk akseptabelt salt, saerling hydrokloridet
WO2004064778A3 (en)	2005-05-12	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007070434A3 (en)	2008-03-06	Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
PL366726A1 (pl)	2005-02-07	4'-podstawione nukleozydy
WO2006078676A3 (en)	2007-03-29	Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007114827A8 (en)	2009-01-15	Substituted heterocyclic compounds and methods of use
MA28747B1 (fr)	2007-07-02	Dérivés de pyridine
TWI348371B (pl)	2011-09-11
MY147984A (en)	2013-02-28	Pyrimidine derivatives
MA29926B1 (fr)	2008-11-03	Derives de pyrazine
WO2007070598A3 (en)	2008-10-30	Nucleotide and oligonucleotide prodrugs
EP2635124A1 (en)	2013-09-11	Alkylsulfinyl-substituted thiazolide compounds
WO2006023750A3 (en)	2006-07-27	Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007024993A3 (en)	2007-10-11	Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007031829A3 (en)	2007-11-08	Novel pyrimidine carboxamides
TWI256890B (en)	2006-06-21	Hetero biaryl derivatives as matrix metalloproteinase inhibitors
WO2007083182A3 (en)	2007-11-15	Novel heterocycles